loader from loading.io

Peter Hendricks Ph.D. – Is Psilocybin Helpful For People Who Abuse Cocaine?

Psychedelics Today

Release Date: 06/30/2020

PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking show art PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Psychedelics Today

(Brighton, UK) joins Joe Moore for a grounded conversation on the boom in functional mushrooms and why the category may be moving too quickly. As the founder of , Oli works with consumers and brands to demystify functional mushrooms, with a focus on education, traceability, and realistic expectations. The conversation begins with a critique of wellness hype cycles. Oli explains how consumer desperation for help with anxiety, sleep, stress, and cognition can create an opening for a rapid wave of products that are not always grounded in careful sourcing or clear science. Using as a case...

info_outline
PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation show art PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation

Psychedelics Today

In this live episode, joins to discuss . She explains why many Indigenous initiatory systems begin with consultation and careful assessment of the person, often using divination and lineage-based diagnostic methods before anyone enters ceremony. Eastman contrasts that with modern frameworks that can move fast, rely on short trainings, or treat the medicine as a stand-alone intervention. Early Themes: Ritual, Preparation, and the Loss of Container Eastman describes her background, including ancestral roots in Mexico and her later work at Crossroads Ibogaine in Mexico, where she supported...

info_outline
PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy show art PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Psychedelics Today

Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director of , the legislative director at , and a key strategist behind Texas’ landmark interest in ibogaine research. He also advises for . His work sits at the intersection of science, policy, and lived experience, and this conversation offers a clear look into what is happening right now. Early Themes: The Rise of State Advocacy Davidson explains how he entered politics at nineteen and how his...

info_outline
PT 642 - Michael Sapiro PhD - Truth Medicine, Psychedelics, and Living Your Truth show art PT 642 - Michael Sapiro PhD - Truth Medicine, Psychedelics, and Living Your Truth

Psychedelics Today

In this episode, joins Kyle Buller to explore truth, healing, and psychedelic-assisted psychotherapy through the lens of his new book, . A clinical psychologist, ordained Zen Buddhist monk, retreat leader, and fellow at the Institute of Noetic Sciences, he blends Buddhist psychology, trauma work, and consciousness studies. The discussion focuses on how people discover and live their truth, and why that truth becomes the core medicine in healing. Early in the Podcast with Michael Sapiro describes how years of clinical work and retreat facilitation shaped his understanding of healing....

info_outline
PT 641 - Joe Moore & Kyle Buller - Holotropic Breathwork, Somatics, and Foundations for Psychedelic Work show art PT 641 - Joe Moore & Kyle Buller - Holotropic Breathwork, Somatics, and Foundations for Psychedelic Work

Psychedelics Today

sits at the center of this wide ranging conversation between Psychedelics Today co-founders Joe Moore and Kyle Buller. Drawing from decades of personal practice and assorted types of breathwork facilitation, they explore how breathwork methods from the Grof lineage including can prepare people for psychedelic work, support difficult journeys, and deepen integration over time. Kyle shares how his near death experience, somatic training, and breathwork facilitation shaped this new course on breathwork foundations, while Joe reflects on how reading Dr Stanislav Grof and years of experience in...

info_outline
PT 640 - Alexander Beiner - Psychedelics, Culture, and the Games We Play show art PT 640 - Alexander Beiner - Psychedelics, Culture, and the Games We Play

Psychedelics Today

Alexander joins Psychedelics Today to explore how psychedelics, culture, and power shape each other. A writer, facilitator, and co founder of the conference and the media platform , he has spent years thinking about how psychedelic experiences ripple into politics, economics, conflict, and community. In this episode, he and Joe trace the path from early internet forums to today’s psychedelic renaissance, and ask what it would mean to bring a truly psychedelic perspective into our institutions. Beiner is less interested in psychedelics as a niche medical tool and more interested in how they...

info_outline
PT 639 - Evelyn Eddy Shoop PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care show art PT 639 - Evelyn Eddy Shoop PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care

Psychedelics Today

Overview Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science. Early Themes: Injury, OCD, and Choosing Psychiatry Early in the episode, Evelyn...

info_outline
PT 638 - Dr Jason Konner - Psychedelic Oncologist show art PT 638 - Dr Jason Konner - Psychedelic Oncologist

Psychedelics Today

In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at to devote himself to the emerging intersection of cancer care and psychedelics. Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply , though he didn’t have that language for it at the time. A chance moment in a yoga class, overhearing someone say “ retreat” just before he was scheduled for hernia surgery, became the turning point....

info_outline
PT 637 - Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration show art PT 637 - Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

Psychedelics Today

Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused...

info_outline
PT 636 - Dr. Ros Watts – Building Communities and Connection show art PT 636 - Dr. Ros Watts – Building Communities and Connection

Psychedelics Today

Clinical psychologist joins to share insights from her decade of work with and her evolving focus on community-based integration. As the former Clinical Lead for , Dr. Watts witnessed how psychedelic experiences can foster profound feelings of — to self, others, and nature — yet also how that connection can fade without ongoing support. In this conversation, she reflects on what years of research have taught her about connectedness as both a healing mechanism and a human need. She explores how can transform fleeting psychedelic breakthroughs into lasting change, and why community is...

info_outline
 
More Episodes

In this episode, Joe speaks with Peter Hendricks, Ph.D. and Associate Professor at the University of Alabama, currently involved in researching the effects of psilocybin on people dealing with cocaine-related substance use disorder. 

He discusses the details of the pilot trial (following the Johns Hopkins model, with music created by Bill Richards), some early findings and speculations, what music might work best for these sessions, how excited he is to bring these findings to the criminal justice system, and how religion and tribalism come into play when looking at what people get out of these psychedelic experiences.

Hendricks points out that while psilocybin is currently being researched as a treatment for tobacco use (by Matthew Johnson at Johns Hopkins) and alcohol use (by Michael Bogenschutz at NYU), this is the first large study with cocaine and could lead to the first medication for major stimulants. And while there have been many studies on psilocybin in general, they’ve rarely been focused on the people he’s working with, who are often poorer, less educated, often out of work, and usually struggling more than those typically involved in these studies. They also talk about what research of the past has given us data-wise, and how inspirational it has been to the work being done today. 

Notable Quotes

“The participants in our trial- they haven’t read Michael Pollan’s book or others. They’re not in the know. I’ll have to explain to them what the drug is, and the common reaction is, ‘uhh, so you’re going to help me stop getting high by getting me high?’ and I’ll try to explain how the drug might differ from others, from more addictive drugs like cocaine. And as we know, it’s an ineffable experience- it’s a difficult experience to put to words…. I’m honored and I have admiration for our participants because they have the courage to dive into this study conducted at a University by people they’ve never met. It can be a very frightening experience and they say, ‘you know what, I’ve tried everything. At this point, I’m desperate, let’s give it a try.’ I probably couldn’t overstate how much courage it takes for them to do what they do. I don’t know that I could do it myself.” 

“I think for most of the world’s fates, the tenants are that we’re all in this together, and we’re bound by love. And that really might be the message that most people get from psychedelics, but similar to religion, sometimes that message is perverted a bit and what you take from it is, ‘my in-group is what’s most important and I’m going to act to preserve my own tribe, even if it means treating others in an awful, inhumane way…’ Sometimes experiences that are really meant to foster a connection with everybody can go haywire and we have to be aware of that”

“One criticism of some of the studies conducted so far has been, how do we know that psilocybin might have these effects on a sample that isn’t all college-educated or doctorates or who are Professors at Universities who make more than 100,000 dollars per year and live comfortably? How do we know that this experience would have any meaning to somebody who’s making less than 10,000 per year, who has a fifth-grade education, who’s unemployed and homeless? I think in large part, this study might answer that question. If we find an effect, then we can say it appears to also have an effect among those who look different and whose life circumstances are much different than some of the earlier participants.”

Links

Twitter

Heffter Research Institute

Support the show

Navigating Psychedelics


About Peter Hendricks PhD

Dr. Hendricks received his doctorate in clinical psychology from the University of South Florida and completed a post-doctoral Fellowship in Drug Abuse Treatment and Services Research at the University of California, San Francisco. His research centers on the development of novel and potentially more effective treatments for substance dependence, with specific areas of focus on tobacco, cocaine, and polysubstance dependence in vulnerable populations.